Sanofi, GlaxoSmithKline Launches New COVID Vaccine Study

Sanofi and GlaxoSmithKline have launched a new study of their coronavirus vaccine after disappointing results from previous tests.

The drug makers pushed back the rollout of their experimental COVID-19 shot in December as a study found an “inadequate” immune response to the virus occurred in people over 50 years of age.

The now plan to prepare the vaccine and test three different doses in a new Phase 2 study of 720 adults in the US, Honduras and Panama. According to Monday’s news.

“We are confident that our vaccine candidate has strong potential and are encouraged by the latest preclinical data,” said Thomas Triomphe, head of vaccine business at Sanofi. “This new Phase 2 study will enable us to identify the final vaccine formulation for adults of all ages.”

If the study goes well, Sanofi and GlaxoSmithKline plan to begin a large-scale Phase 3 trial in the spring and obtain regulatory approval in the second half of this year.

The vaccine – which will be administered in two shots given three weeks apart in the Phase 2 study – will be made available in the final three months of 2021 if it is approved, European said.

Sanofi and GlaxoSmithKline are outpacing other pharmaceutical manufacturers in the race to deliver COVID-19 inoculations, despite being two of the world’s largest vaccine businesses.

Sanofi Stated separately On Monday, it will help Johnson & Johnson build its own one-dose coronavirus vaccine, which is currently awaiting emergency use authorization from the Food and Drug Administration.

Sanofi expects its factory in Marcy l’Etoile, France to shoot about 12 million doses of Johnson & Johnson per month.

The Paris-based company has announced plans to help Pfizer and BioNTech produce more than 125 million doses of its vaccines, which are currently being distributed in the US.

On Monday, Sanofi’s stock price plummeted 0.2 percent to $ 46.53 by 7:39 in prepaid trading, while GlaxoSmithKline shares were trading nearly flat at $ 34.42 recently.

Be the first to comment

Leave a Reply

Your email address will not be published.


*